Iptacopan in IgA Nephropathy - Final 24-Month Data - PubMed
3 hours ago
- #Complement inhibition
- #IgA nephropathy
- #Iptacopan
- Iptacopan, a complement factor B inhibitor, showed efficacy in IgA nephropathy over 24 months with slower eGFR decline compared to placebo.
- The annualized total eGFR slope was -3.10 ml/min/1.73 m²/year with iptacopan vs -6.12 with placebo (difference of 3.02 ml/min/1.73 m²/year; P<0.001).
- A composite kidney-failure endpoint occurred in 21.4% of iptacopan patients vs 33.5% with placebo (hazard ratio 0.57; P=0.003).
- Safety profile was acceptable, with adverse events in 87.0% (iptacopan) and 89.1% (placebo), and serious adverse events in 12.2% vs 11.7%.
- The trial was a phase 3 study involving 477 adults with IgA nephropathy and proteinuria despite supportive care.